What determines skin sensitization potency: Myths, maybes and realities. The 500 molecular weight cut‐off: An updated analysis
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Applied Toxicology"
DOI: 10.1002/jat.3348
Abstract: It is widely accepted that substances must have a molecular weight (MW) < 500 to penetrate effectively through the skin to induce sensitization. Roberts et al. (2012. Contact Dermatitis 68: 32–41) evaluated a data set… read more here.
Keywords: updated analysis; chemistry; skin sensitization; molecular weight ... See more keywords
Long-Term Follow-up of Tisagenlecleucel in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Updated Analysis of Juliet Study
Sign Up to like & getrecommendations! Published in 2019 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2018.12.089
Abstract: Background Tisagenlecleucel, a chimeric antigen receptor T-cell therapy, has demonstrated efficacy and manageable safety in adult patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) in the global, multicenter, pivotal, phase 2, JULIET trial… read more here.
Keywords: updated analysis; cell; relapsed refractory; analysis ... See more keywords
Updated Analysis Confirms Sustained Poor Prognosis of COVID-19 in Patients with Lymphoma in Latin America: A Cohort of 160 Patients from Gell
Sign Up to like & getrecommendations! Published in 2021 at "Blood"
DOI: 10.1182/blood-2021-153875
Abstract: Updated analysis confirms sustained poor prognosis of COVID-19 in patients with lymphoma in Latin America: A cohort of 160 patients from GELL. Introduction: Ongoing SARS-COV-2 pandemic has impacted the management of cancer patients worldwide. Several… read more here.
Keywords: analysis; updated analysis; latin america; honoraria ... See more keywords
Updated analysis of the inducible T-cell co-stimulatory receptor (ICOS) agonist, GSK3359609 (GSK609), combination with pembrolizumab (PE) in patients (pts) with anti-PD-1/L1 treatment-naïve head and neck squamous cell carcinoma (HNSCC).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.6517
Abstract: 6517Background: INDUCE-1 (NCT02723955) is a first-in-human study investigating GSK609, an IgG4 ICOS agonist non-T-cell depleting antibody, as monotherapy and combination therapy with anti-cancer ag... read more here.
Keywords: combination; analysis inducible; updated analysis; inducible cell ... See more keywords
Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, +/- bortezomib, in patients with relapsed/refractory multiple myeloma.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.8511
Abstract: 8511Background: Venetoclax (Ven) is a selective, potent, oral BCL-2 inhibitor that induces apoptosis in multiple myeloma (MM) cells in vitro. It has shown synergistic activity with bortezomib (V) a... read more here.
Keywords: analysis phase; myeloma; updated analysis; multiple myeloma ... See more keywords
Hospital at Home in an oncology setting: Updated analysis.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2022.40.28_suppl.257
Abstract: 257 Background: Hospitalization at Home (HaH) is an emerging clinical model that delivers the essential elements of acute hospital-level care in the home and has demonstrated efficacy largely for inpatient medical conditions. Few programs have… read more here.
Keywords: oncology; hah admission; hah; updated analysis ... See more keywords